Professor Dr Chan Siew Pheng
, 3 days ago
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.
An estimated 463 million adults – about one in 11 – had diabetes in 2019. These numbers are expected to rise to 700 million by 2045. Worse, one in two people are undiagnosed. [https://www.idf.org/, accessed 19 October 2020]
In patients with type 2 diabetes (T2D), once-weekly doses of the dual glucose-dependent insulinotropic polypeptide–GLP-1* receptor agonist tirzepatide for 40 weeks resulted in superior HbA1c reductions compared with the GLP-1 receptor agonist semaglutide, according to results from the phase III SURPASS-2** trial presented at ADA 2021.
In patients with type 2 diabetes (T2D) with cardiovascular (CV) risk factors or impaired kidney function, weekly doses of the exendin-based GLP-1* receptor agonist (RA) efpeglenatide may reduce their risk of major adverse cardiovascular events (MACE) or kidney outcomes, according to findings from the AMPLITUDE-O trial presented at ADA 2021.